The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Schwannomas and Their Pathogenesis
Open accessAbstract
Schwannomas may occur spontaneously, or in the context of a familial tumor syndrome such as neurofibromatosis type 2 (NF 2), schwannomatosis and C arney's complex. Schwannomas have a variety of morphological appearances, but they behave as World Health Organization (WHO) grade I tumors, and only very rarely undergo malignant transformation. Central to the pathogenesis of these tumors is loss of function of merlin, either by direct genetic change involving the NF2 gene on chromosome 22 or secondarily to merlin inactivation. The genetic pathways and morphological features of schwannomas associated with different genetic syndromes will be discussed. Merlin has multiple functions, including within the nucleus and at the cell membrane, and this review summarizes our current understanding of the mechanisms by which merlin loss is involved in schwannoma pathogenesis, highlighting potential areas for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rouleau, G. A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., Plougastel, B., et al. (1993) · Nature · doi:10.1038/363515a0 · Cited by 1,420
Trofatter, J. (1993) · Cell · doi:10.1016/0092-8674(93)90406-g · Cited by 1,403
Kirschner, L. S., Carney, J. A., Pack, S. D., Taymans, S. E., Giatzakis, C., Cho, Y. S., Cho-Chung, Y. S., & Stratakis, C. A. (2000) · Nature Genetics · doi:10.1038/79238 · Cited by 1,153
Tumors of the Brain and Nervous System after Radiotherapy in Childhood
Ron, E., Modan, B., Boice, J. D., Alfandary, E., Stovall, M., Chetrit, A., & Katz, L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810203191601 · Cited by 934
Wajapeyee, N., Serra, R. W., Zhu, X., Mahalingam, M., & Green, M. R. (2008) · Cell · doi:10.1016/j.cell.2007.12.032 · Cited by 903 · cited 1×
“LZTR1 is a tumor suppressor gene that is lost in a subset of glioblastomas (63), and although it may have several functions, it may interact with proteins that regulate SMARCB1 expression (139, 143, 188).”
BackgroundStratakis, C. A., Kirschner, L. S., & Carney, J. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4041 · Cited by 826
Zhang, N., Bai, H., David, K. K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu, P., Anders, R. A., & Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.06.015 · Cited by 804
Lessard, J., Wu, J. I., Ranish, J. A., Wan, M., Winslow, M. M., Staahl, B. T., Wu, H., Aebersold, R., Graef, I. A., & Crabtree, G. R. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.019 · Cited by 735
An atlas of combinatorial transcriptional regulation in mouse and man
Ravasi, T., Suzuki, H., Cannistraci, C. V., Katayama, S., Bajic, V. B., Tan, K., Akalin, A., Schmeier, S., Kanamori-Katayama, M., Bertin, N., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.044 · Cited by 715 · cited 1×
“LZTR1 is a tumor suppressor gene that is lost in a subset of glioblastomas (63), and although it may have several functions, it may interact with proteins that regulate SMARCB1 expression (139, 143, 188).”
BackgroundA Clinical Study of Type 2 Neurofibromatosis
(1992) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068699 · Cited by 634
Morrison, H., Sherman, L. S., Legg, J., Banine, F., Isacke, C., Haipek, C. A., Gutmann, D. H., Ponta, H., & Herrlich, P. (2001) · Genes & Development · doi:10.1101/gad.189601 · Cited by 536
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Plotkin, S. R., Stemmer-Rachamimov, A. O., Barker, F. G., Halpin, C., Padera, T. P., Tyrrell, A., Sorensen, A. G., Jain, R. K., & di Tomaso, E. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902579 · Cited by 532
The integrated landscape of driver genomic alterations in glioblastoma
Frattini, V., Trifonov, V., Chan, J. M., Castano, A., Lia, M., Abate, F., Keir, S. T., Ji, A. X., Zoppoli, P., Niola, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2734 · Cited by 524
Yu, J., Zheng, Y., Dong, J., Klusza, S., Deng, W.-M., & Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2009.12.012 · Cited by 496
Evans, D. G., Huson, S. M., Donnai, D., Neary, W., Blair, V, Teare, D., Newton, V, Strachan, T., Ramsden, R., & Harris, R. (1992) · Journal of Medical Genetics · doi:10.1136/jmg.29.12.841 · Cited by 468
Stratakis, C. A., Carney, J. A., Lin, J. P., Papanicolaou, D. A., Karl, M., Kastner, D. L., Pras, E., & Chrousos, G. P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118467 · Cited by 459
Bertherat, J., Horvath, A., Groussin, L., Grabar, S., Boikos, S., Cazabat, L., Libe, R., René-Corail, F., Stergiopoulos, S., Bourdeau, I., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2333 · Cited by 449
Parry, D. M., Eldridge, R., Kaiser‐Kupfer, M. I., Bouzas, E. A., Pikus, A., & Patronas, N. (1994) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320520411 · Cited by 421
Evans, D. G. R., Moran, A., King, A., Saeed, S., Gurusinghe, N., & Ramsden, R. (2005) · Otology & Neurotology · doi:10.1097/00129492-200501000-00016 · Cited by 418
Diagnostic criteria for schwannomatosis
MacCollin, M., Chiocca, E. A., Evans, D. G., Friedman, J. M., Horvitz, R., Jaramillo, D., Lev, M., Mautner, V. F., Niimura, M., Plotkin, S. R., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000163982.78900.ad · Cited by 417
Germline Mutation of INI1/SMARCB1 in Familial Schwannomatosis
Hulsebos, T. J. M., Plomp, A. S., Wolterman, R. A., Robanus-Maandag, E. C., Baas, F., & Wesseling, P. (2007) · The American Journal of Human Genetics · doi:10.1086/513207 · Cited by 398
McClatchey, A. I., Saotome, I., Mercer, K., Crowley, D., Gusella, J. F., Bronson, R. T., & Jacks, T. (1998) · Genes & Development · doi:10.1101/gad.12.8.1121 · Cited by 388
Giovannini, M., Robanus-Maandag, E., van der Valk, M., Niwa-Kawakita, M., Abramowski, V., Goutebroze, L., Woodruff, J. M., Berns, A., & Thomas, G. (2000) · Genes & Development · doi:10.1101/gad.14.13.1617 · Cited by 369
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin
Curto, M., Cole, B. K., Lallemand, D., Liu, C.-H., & McClatchey, A. I. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703010 · Cited by 363
Bianchi, A. B., Mitsunaga, S. I., Cheng, J. Q., Klein, W. M., Jhanwar, S. C., Seizinger, B., Kley, N., Klein-Szanto, A. J., & Testa, J. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.10854 · Cited by 360
The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling
Shaw, R. J., Paez, J. G., Curto, M., Yaktine, A., Pruitt, W. M., Saotome, I., O'Bryan, J. P., Gupta, V., Ratner, N., Der, C. J., et al. (2001) · Developmental Cell · doi:10.1016/s1534-5807(01)00009-0 · Cited by 343
Antinheimo, J., Sankila, R., Carpén, O., Pukkala, E., Sainio, M., & Jääskeläinen, J. (2000) · Neurology · doi:10.1212/wnl.54.1.71 · Cited by 338
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
Lallemand, D., Curto, M., Saotome, I., Giovannini, M., & McClatchey, A. I. (2003) · Genes & Development · doi:10.1101/gad.1054603 · Cited by 324
Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus
Li, W., You, L., Cooper, J., Schiavon, G., Pepe-Caprio, A., Zhou, L., Ishii, R., Giovannini, M., Hanemann, C. O., Long, S. B., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.029 · Cited by 321
Self-citationPiotrowski, A., Xie, J., Liu, Y. F., Poplawski, A. B., Gomes, A. R., Madanecki, P., Fu, C., Crowley, M. R., Crossman, D. K., Armstrong, L., et al. (2014) · Nature Genetics · doi:10.1038/ng.2855 · Cited by 315
The Neuroimaging and Clinical Spectrum of Neurofibromatosis 2
Mautner, V.-F., Lindenau, M., Baser, M. E., Hazim, W., Tatagiba, M., Hasse, W., Samii, M., Wais, R., & Pulst, S.-M. (1996) · Neurosurgery · doi:10.1097/00006123-199605000-00004 · Cited by 301
Evans, D. G. R., Birch, J. M., Ramsden, R. T., Sharif, S., & Baser, M. E. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.036319 · Cited by 301
Descriptive epidemiology of vestibular schwannomas1
Propp, J. M., McCarthy, B. J., Davis, F. G., & Preston-Martin, S. (2006) · Neuro-Oncology · doi:10.1215/s1522851704001097 · Cited by 273
Yi, C., Troutman, S., Fera, D., Stemmer-Rachamimov, A., Avila, J. L., Christian, N., Persson, N. L., Shimono, A., Speicher, D. W., Marmorstein, R., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.017 · Cited by 260
Common Pathogenetic Mechanism for Three Tumor Types in Bilateral Acoustic Neurofibromatosis
Seizinger, B. R., Rouleau, G. A., Ozelius, L. J., et al. (1987) · Science · doi:10.1126/science.3105060 · Cited by 256
Mucocutaneous lentigines, cardiomucocutaneous myxomas, and multiple blue nevi: The “LAMB” syndrome
Rhodes, A. R., Silverman, R. A., Harrist, T. J., & Pérez‐Atayde, A. R. (1984) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(84)80047-x · Cited by 238
Cell Cycle Arrest and Repression of Cyclin D1 Transcription by INI1/hSNF5
Zhang, Z.-K., Davies, K. P., Allen, J., Zhu, L., Pestell, R. G., Zagzag, D., & Kalpana, G. V. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5975-5988.2002 · Cited by 233
Interdomain binding mediates tumor growth suppression by the NF2 gene product
Sherman, L., Xu, H.-M., Geist, R. T., Saporito-Irwin, S., Howells, N., Ponta, H., Herrlich, P., & Gutmann, D. H. (1997) · Oncogene · doi:10.1038/sj.onc.1201418 · Cited by 230
Merlin/Neurofibromatosis Type 2 Suppresses Growth by Inhibiting the Activation of Ras and Rac
Morrison, H., Sperka, T., Manent, J., Giovannini, M., Ponta, H., & Herrlich, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1608 · Cited by 223
Evaluation of clinical diagnostic criteria for neurofibromatosis 2
Baser, M. E., Friedman, J. M., Wallace, A. J., Ramsden, R. T., Joe, H., & Evans, D. G. R. (2002) · Neurology · doi:10.1212/01.wnl.0000035638.74084.f4 · Cited by 222
Betz, B. L., Strobeck, M. W., Reisman, D. N., Knudsen, E. S., & Weissman, B. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205706 · Cited by 212
The Prevalence of “Incidental” Acoustic Neuroma
Lin, D., Hegarty, J. L., Fischbein, N. J., & Jackler, R. K. (2005) · Archives of Otolaryngology–Head & Neck Surgery · doi:10.1001/archotol.131.3.241 · Cited by 203
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria
Plotkin, S. R., Blakeley, J. O., Evans, D. G., Hanemann, C. O., Hulsebos, T. J. M., Hunter‐Schaedle, K., Kalpana, G. V., Korf, B., Messiaen, L., Papi, L., et al. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35760 · Cited by 187
Self-citationKarajannis, M. A., Legault, G., Hagiwara, M., Ballas, M. S., Brown, K., Nusbaum, A. O., Hochman, T., Goldberg, J. D., Koch, K. M., Golfinos, J. G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos146 · Cited by 182
Kirschner, L. S., Kusewitt, D. F., Matyakhina, L., Towns, W. H., Carney, J. A., Westphal, H., & Stratakis, C. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0580 · Cited by 175
Kluwe, L., Mautner, V, Heinrich, B., Dezube, R., Jacoby, L. B., Friedrich, R. E., & MacCollin, M. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.2.109 · Cited by 173
Veugelers, M., Wilkes, D. C., Burton, K. A., McDermott, D. A., Song, Y., Goldstein, M. M., Perle, K. L., Vaughan, C. J., O'Hagan, A. H., Bennett, K. R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405535101 · Cited by 163
Functional inactivation of NF2/merlin in human mesothelioma
Thurneysen, C., Opitz, I., Kurtz, S., Weder, W., Stahel, R. A., & Felley‐Bosco, E. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.08.014 · Cited by 162
Lallemand, D., Manent, J., Couvelard, A., Watilliaux, A., Siena, M., Chareyre, F., Lampin-Saint-Amaux, A., Niwa‐Kawakita, M., Kalamarides, M., & Giovannini, M. (2008) · Oncogene · doi:10.1038/onc.2008.427 · Cited by 148
Brg1 is required for murine neural stem cell maintenance and gliogenesis
Matsumoto, S., Banine, F., Struve, J., Xing, R., Adams, C., Liu, Y., Metzger, D., Chambon, P., Rao, M. S., & Sherman, L. S. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2005.10.044 · Cited by 147 · cited 1×
“SMARCB1 protein forms part of an adenosine triphosphate (ATP)-dependant chromatin remodeling complex, important in central nervous system (CNS) development (107, 117) and has tumor suppressor functions including induction of cell cycle arrest, associated with downregulation of cyclin D1 (207) and upregulation of p16 (…”
BackgroundAlfthan, K., Heiska, L., Grönholm, M., Renkema, G. H., & Carpén, O. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313916200 · Cited by 142
Baser, M. E., Kuramoto, L., Joe, H., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/422700 · Cited by 138
Ammoun, S., Flaiz, C., Ristic, N., Schuldt, J., & Hanemann, C. O. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5849 · Cited by 138
Self-citationGermline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas
Christiaans, I., Kenter, S. B., Brink, H. C., van Os, T. A. M., Baas, F., van den Munckhof, P., Kidd, A., & Hulsebos, T. J. M. (2010) · Journal of Medical Genetics · doi:10.1136/jmg.2010.082420 · Cited by 136
Rong, R., Surace, E. I., Haipek, C. A., Gutmann, D. H., & Ye, K. (2004) · Oncogene · doi:10.1038/sj.onc.1207794 · Cited by 134
Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2
Sperfeld, A. D., Hein, C., Schröder, J. M., et al. (2002) · Brain · doi:10.1093/brain/awf115 · Cited by 131
Wong, H. K., Lahdenranta, J., Kamoun, W. S., Chan, A. W., McClatchey, A. I., Plotkin, S. R., Jain, R. K., & di Tomaso, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3107 · Cited by 129
Casadei, G. P., Scheithauer, B. W., Hirose, T., Manfrini, M., van Houton, C., & Wood, M. B. (1995) · Cancer · doi:10.1002/1097-0142(19950301)75:5<1109::aid-cncr2820750510>3.0.co;2-m · Cited by 129
Universal absence of merlin, but not other ERM family members, in schwannomas.
Stemmer-Rachamimov, A. O., Xu, L., Gonzalez-Agosti, C., Burwick, J. A., Pinney, D., Beauchamp, R. L., Jacoby, L. B., Gusella, J. F., Ramesh, V., & Louis, D. N. (1997) · PubMed · Cited by 125
Malignant peripheral nerve sheath tumours in inherited disease
Evans, D. G., Huson, S., & Birch, J. M. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-17 · Cited by 123
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells
Kaempchen, K., Mielke, K., Utermark, T., Langmesser, S., & Hanemann, C. O. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg146 · Cited by 120
Self-citationShedding light on Merlin's wizardry
Okada, T., You, L., & Giancotti, F. G. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.03.006 · Cited by 117
Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients
Plotkin, S. R., Halpin, C. F., McKenna, M. J., Loeffler, J. S., Batchelor, T. T., & Barker, F. G. (2010) · Otology & Neurotology · doi:10.1097/mao.0b013e3181eb328a · Cited by 114
The merlin tumor suppressor localizes preferentially in membrane ruffles.
Gonzalez-Agosti, C., Xu, L., Pinney, D., Beauchamp, R. L., Hobbs, W., Gusella, J. F., & Ramesh, V. (1996) · PubMed · Cited by 113
Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2–Deficient Target Cell Types
James, M. F., Stivison, E., Beauchamp, R. L., Han, S., Li, H., Wallace, M. R., Gusella, J. F., Stemmer-Rachamimov, A. O., & Ramesh, V. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0425-t · Cited by 112
Clinical phenotypes and molecular genetic mechanisms of Carney complex
Wilkes, D. C., McDermott, D. A., & Basson, C. T. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70244-8 · Cited by 110
Yokoyama, T., Osada, H., Murakami, H., Tatematsu, Y., Taniguchi, T., Kondo, Y., Yatabe, Y., Hasegawa, Y., Shimokata, K., Horio, Y., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn200 · Cited by 110
Large Deletions of the PRKAR1A Gene in Carney Complex
Horvath, A., Bossis, I., Giatzakis, C., Levine, E., Weinberg, F. D., Meoli, E., Robinson-White, A. J., Siegel, J., Soni, P., Groussin, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1155 · Cited by 110
A Clue to the Therapy of Neurofibromatosis Type 2: NF2/Merlin Is a PAK1 Inhibitor
Hirokawa, Y., Tikoo, A., Huynh, J., Utermark, T., Hanemann, C. O., Giovannini, M., Xiao, G., Testa, J. R., Wood, J. L., & Maruta, H. (2004) · The Cancer Journal · doi:10.1097/00130404-200401000-00006 · Cited by 109
Self-citationCheng, H.-L., Randolph, A. E., Yee, D., Delafontaine, P., Tennekoon, G. I., & Feldman, E. L. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66020525.x · Cited by 108
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma
Ammoun, S., Cunliffe, C. H., Allen, J. C., Chiriboga, L. A., Giancotti, F. G., Zagzag, D., Hanemann, C. O., & Karajannis, M. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq012 · Cited by 107
Self-citationZhou, L., Ercolano, E., Ammoun, S., Schmid, M. C., Barczyk, M., & Hanemann, C. O. (2011) · Neoplasia · doi:10.1593/neo.111060 · Cited by 105
Self-citationTumor-Associated Macrophages Are Related to Volumetric Growth of Vestibular Schwannomas
de Vries, M. W., Bruijn, I. H. B., Malessy, M. J. A., de Bruïne, S. F. T., van der Mey, A. G. L., & Hogendoorn, P. C. W. (2013) · Otology & Neurotology · doi:10.1097/mao.0b013e31827c9fbf · Cited by 99
Bai, Y., Liu, Y.-J., Wang, H., Xu, Y., Stamenkovic, I., & Yu, Q. (2006) · Oncogene · doi:10.1038/sj.onc.1209849 · Cited by 96
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation
Sekido, Y. (2011) · Pathology International · doi:10.1111/j.1440-1827.2011.02666.x · Cited by 95
Demetriades, A. K., Saunders, N. C., Rose, P., Fisher, C., Rowe, J. G., Tranter, R., & Hardwidge, C. (2010) · Skull base · doi:10.1055/s-0030-1253576 · Cited by 95
Fraenzer, J.-T., Pan, H., Minimo, L., et al. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.6.1493 · Cited by 93
Comparative Pathology of Nerve Sheath Tumors in Mouse Models and Humans
Stemmer-Rachamimov, A. O., Louis, D. N., Nielsen, G. P., Antonescu, C. R., Borowsky, A. D., Bronson, R. T., Burns, D. K., Cervera, P., McLaughlin, M. E., Reifenberger, G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4079 · Cited by 93
Stratakis, C. A., Jenkins, R. B., Pras, E., Mitsiadis, C. S., Raff, S. B., Stalboerger, P. G., Tsigos, C., Carney, J. A., & Chrousos, G. P. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.10.8855810 · Cited by 92
Interdomain Interaction of Merlin Isoforms and Its Influence on Intermolecular Binding to NHE-RF
Gonzalez-Agosti, C., Wiederhold, T., Herndon, M. E., Gusella, J. F., & Ramesh, V. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.34438 · Cited by 91
Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival
Ammoun, S., Provenzano, L., Zhou, L., Barczyk, M., Evans, K., Hilton, D. A., Hafizi, S., & Hanemann, C. O. (2013) · Oncogene · doi:10.1038/onc.2012.587 · Cited by 88
Self-citationEmerging therapeutic targets in schwannomas and other merlin-deficient tumors
Ammoun, S., & Hanemann, C. O. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.82 · Cited by 86
Self-citationKino, T., Takeshima, H., Nakao, M., Nishi, T., Yamamoto, K., Kimura, T., Saito, Y., Kochi, M., Kuratsu, J., Saya, H., et al. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00432.x · Cited by 84
Houshmandi, S. S., Emnett, R. J., Giovannini, M., & Gutmann, D. H. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01392-08 · Cited by 82
The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene
Baser, M. E., & Database, A. T. C. T. T. I. N. M. (2006) · Human Mutation · doi:10.1002/humu.20317 · Cited by 81
de Vries, M. W., Hogendoorn, P. C. W., Bruyn, I. B.-D., Malessy, M. J. A., & van der Mey, A. G. L. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1236-9 · Cited by 77
Sher, I., Hanemann, C. O., Karplus, P. A., & Bretscher, A. P. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.03.008 · Cited by 75
Self-citationMerlin/ERM proteins establish cortical asymmetry and centrosome positionPreprint
Hebert, A. M., DuBoff, B., Casaletto, J. B., Gladden, A. B., & McClatchey, A. I. (2012) · Genes & Development · doi:10.1101/gad.194027.112 · Cited by 74
CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas
González‐Gómez, P., Bello, M. J., Alonso, M. E., Lomas, J., Arjona, D., de Campos, J. M., Vaquero, J., Isla, A., Lassaletta, L., Gutiérrez, M., et al. (2003) · PubMed · doi:10.5281/zenodo.10617916 · Cited by 67
Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin
Muranen, T. E., Grönholm, M., Renkema, G. H., & Carpén, O. (2004) · Oncogene · doi:10.1038/sj.onc.1208283 · Cited by 66
IGF-I promotes Schwann cell motility and survival via activation of Akt
Cheng, H. T., Steinway, M. L., Delaney, C. L., Franke, T. F., & Feldman, E. L. (2000) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00324-5 · Cited by 63
Laulajainen, M., Muranen, T. E., Carpén, O., & Grönholm, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210988 · Cited by 61
Constitutive neuregulin‐1/ErbB signaling contributes to human vestibular schwannoma proliferation
Hansen, M. R., Roehm, P. C., Chatterjee, P., et al. (2006) · Glia · doi:10.1002/glia.20316 · Cited by 58
Stonecypher, M. S., Chaudhury, A. R., Byer, S. J., & Carroll, S. L. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000199575.93794.2f · Cited by 57
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2
Ammoun, S., Schmid, M. C., Triner, J., Manley, P. W., & Hanemann, C. O. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor056 · Cited by 54
Self-citationCooper, J. M., Li, W., You, L., Schiavon, G., Pepe-Caprio, A., Zhou, L., Ishii, R., Giovannini, M., Hanemann, C. O., Long, S. B., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2002314 · Cited by 53
Self-citationTemporal Control of Rac in Schwann Cell–Axon Interaction Is Disrupted inNF2-Mutant Schwannoma Cells
Nakai, Y., Zheng, Y., MacCollin, M., & Ratner, N. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4865-05.2006 · Cited by 53
Ammoun, S., Schmid, M. C., Zhou, L., Ristic, N., Ercolano, E., Hilton, D. A., Perks, C. M., & Hanemann, C. O. (2011) · Oncogene · doi:10.1038/onc.2011.357 · Cited by 51
Self-citationDistribution of collagen type IV in soft tissue tumors: An immunohistochemical study
Ogawa, K., Oguchi, M., Yamabe, H., Nakashima, Y., & Hamashima, Y. (1986) · Cancer · Cited by 50
Grönholm, M., Teesalu, T., Tyynelä, J., Piltti, K. M., Böhling, T., Wartiovaara, K., Vaheri, A. I., & Carpén, O. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.11.014 · Cited by 50
Acoustic neuromas following childhood radiation treatment for benign conditions of the head and neck
Schneider, A. B., Ron, E., Lubin, J. H., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-047 · Cited by 48
Pottier, N., Cheok, M. H.-C., Yang, W., Assem, M., Tracey, L., Obenauer, J. C., Panetta, J. C., Relling, M. V., & Evans, W. E. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm178 · Cited by 42
Hara, T., Bianchi, A. B., Seizinger, B. R., & Kley, N. (1994) · PubMed · Cited by 40
Activation of Ras Requires the ERM-Dependent Link of Actin to the Plasma Membrane
Sperka, T., Geißler, K. J., Merkel, U., Scholl, I., Rubio, I., Herrlich, P. A., & Morrison, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027511 · Cited by 40
Expression of schwannomin in lens and Schwann cells
Claudio, J. O., Veneziale, R. W., Menko, A. S., et al. (1997) · Neuroreport · doi:10.1097/00001756-199705260-00044 · Cited by 38
Merlin in organ size control and tumorigenesis: Hippo versus EGFR?
Yi, C., & Kissil, J. L. (2010) · Genes & Development · doi:10.1101/gad.1964810 · Cited by 37
Genetic Alterations in a Malignant Schwannoma from a Patient with Neurofibromatosis (NF1)
Lothe, R. A., Sæter, G., Danielsen, H. E., Stenwig, A. E., Høyheim, B., O'Connell, P., & Børresen‐Dale, A. (1993) · Pathology - Research and Practice · doi:10.1016/s0344-0338(11)80339-0 · Cited by 34
Laulajainen, M., Muranen, T. E., Nyman, T. A., Carpén, O., & Grönholm, M. (2011) · Neoplasia · doi:10.1593/neo.11356 · Cited by 31
Mast cell frequency in soft tissue tumors: Relation to type and grade of malignancy
Donhuijsen, K., Pastry, M., Völker, B., & Leder, L.-D. (1992) · Pathology - Research and Practice · doi:10.1016/s0344-0338(11)81157-x · Cited by 30
Ammoun, S., Ristic, N., Matthies, C., Hilton, D. A., & Hanemann, C. O. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.017 · Cited by 27
Self-citationThe role of insulin‐like growth factors signaling in merlin‐deficient human schwannomas
Ammoun, S., Schmid, M. C., Ristic, N., Zhou, L., Hilton, D. A., Ercolano, E., Carroll, C., & Hanemann, C. O. (2012) · Glia · doi:10.1002/glia.22391 · Cited by 23
Self-citationRac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors
Manchanda, P., Jones, G. N., Lee, A. A., Pringle, D. R., Zhang, M., Yu, L., Perle, K. M. D. L., & Kirschner, L. S. (2012) · Oncogene · doi:10.1038/onc.2012.374 · Cited by 21
Hirose, T., Ishizawa, K., Sakaki, M., & Fujii, Y. (2012) · Pathology International · doi:10.1111/j.1440-1827.2012.02822.x · Cited by 20
Intraspinal pigmented schwannoma with malignant progression
Röyttä, M., Elfverson, J., & Kalimo, H. (1988) · Acta Neurochirurgica · doi:10.1007/bf01790777 · Cited by 19
Lipid Raft Localization of ErbB2 in Vestibular Schwannoma and Schwann Cells
Brown, K. D., & Hansen, M. R. (2008) · Otology & Neurotology · doi:10.1097/mao.0b013e31815dbb11 · Cited by 17
Expression of ErbB-1 and 2 in vestibular schwannomas
Wickremesekera, A., Hovens, C. M., & Kaye, A. H. (2007) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2007.05.009 · Cited by 14
Cited by
Repair Schwann cell update: Adaptive reprogramming, EMT, and stemness in regenerating nerves
Jessen, K. R., & Arthur‐Farraj, P. (2019) · Glia · doi:10.1002/glia.23532 · Cited by 353
Metadata
- Authors
- Hilton, D. A., & Hanemann, C. O.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2014-02-25
- Volume
- 24
- Issue
- 3
- Pages
- 205-220
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W1539685064
- Cited by
- 309
- References
- 116
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.